Christopher D. Liedl

Associate

liedl-christopher-Full
  • JD, cum laude, Harvard Law School, 2014; executive editor, Harvard Journal of Law & Public Policy; Dean’s Scholar Prizes in Civil Procedure, Criminal Law, and Corporations
  • BBA (Finance, Spanish), summa cum laude, University of Notre Dame Mendoza College of Business, 2008; Beta Gamma Sigma

Qualifications

  • Massachusetts, 2014
  • Boston Bar Association
  • Eastern Association of Intercollegiate Football Officials
  • Association of New England Football Officials
  • Kirkland House Senior Common Room

Christopher D. Liedl

Associate

Christopher Liedl is an associate in the intellectual property transactions and life sciences groups. He advises a range of public and private companies on transactions involving intellectual property, including technology licensing, collaborations, mergers and acquisitions, joint ventures, manufacturing and supply arrangements, copyright and trademark matters, research and development agreements, and other strategic commercial agreements at the intersection of intellectual property and technology. He provides guidance on integrating advice from other legal, business, and subject-matter experts to properly align corporate policies and practices. Christopher also maintains an active pro bono practice, focusing on corporate and intellectual property advice for non-profit organizations, and the representation of individuals from Latin America.

Prior to law school, Christopher worked for Florida-based NextEra Energy Resources in the solar project development, options trading, and asset management departments. During law school, Christopher worked for the Boston Red Sox and the Massachusetts Department of Transportation, in addition to serving as a Harvard College freshman proctor. He currently captains the Ropes & Gray beach volleyball team and officiates football in the NCAA Division II Northeast-10 Conference.

Experience

  • Advised Bain Capital on FDA, DEA, and state regulatory issues relating to its acquisition of Healix, Inc.’s 503B Compounding Pharmacy Services Division.
  • Advised Pfizer Inc. in its acquisition of a minority equity interest in Dutch biopharmaceutical company, AM-Pharma B.V., with an exclusive option to acquire the remaining equity in the company.
  • Represented Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, in its $1.05 billion all-cash divestiture of U.S. license rights to the NUCYNTA® franchise of pharmaceutical products to Depomed, Inc.
  • Advised EMCOR Group, Inc. on drafting proprietary software license agreements, as well as intellectual property aspects of EMCOR’s $205 million acquisition of Ardent Services, L.L.C. and Rabalais Constructors, LLC
  • Counseled on intellectual property matters related to Kohlberg & Co.’s $635 million sale of Pittsburgh Glass Works

Publications